CO20 | Oral semaglutide for 12 months improves microalbuminuria and GFR in type 2 diabetes outpatients

A.M. Labate¹, L. Moretti², M.L. Spina³, E. Allemand², P. Villari⁴ | ¹ASST Mantova Specialistica Ambulatoriale Borgo Mantovano (MN), ²ASST Garda UOC Medicina Interna Po Gavardo (BS), ³ASST Mantova Specialistica Ambulatoriale Asola (MN), ⁴ASST Garda Specialistica Ambulatoriale Po Leno (BS), Italy

Premises and Purpose of the study: In addition to improvement of glycemic control, oral semaglutide has favourable effects on metabolic profile of diabetic patients. Till now kidney function is thought to be little conditioned by oral semaglutide, although injectable semaglutide is under investigation for possible nephro-protective effects, including reduction of microalbuminuria and stabilization of renal function. In this observational study we evaluate the consequences of 12 months treatment with oral semaglutide on renal function, microalbuminuria and main CVD risk factors in 82 type 2 diabetes outpatients, on stable hypoglicemic, anti- hypertensive, lipid lowering therapy.
Materials and Methods: Clinical data, BMI, WC, microalbuminuira, creatinine, metabolic and lipid profile, as well as Visceral Adiposity Index, TYG index and LAP Index were measured in all the patients at baseline and after 12 months of therapy with oral semaglutide.
Results: Treatment with oral semaglutide was associated with significant lowering (p<0,001) from baseline values of microalbuminuria, creatinine, FBG, HbA1c, body weight, BMI, WC, LDL cholesterol, triglycerides, sistolic and diastolic blood pressure, VAI, TYG index, LAP index. Significant (p<0,001) elevation was observed for the values of HDL cholesterol and EGFR.
Conclusions: In this study population 12-month treatment with oral semaglutide in add-on to on-going hypoglicemic therapy significantly improves renal function also reducing levels of microalbuminuria and cutting down all main CVD risk factors and cardiometabolic risk scores.